Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs-a primary or secondary entity?

被引:4
|
作者
Wiesik-Szewczyk, Ewa [1 ]
Kucharczyk, Aleksandra [1 ]
Swierkocka, Katarzyna [2 ]
Rutkowska, Elzbieta [3 ]
Jahnz-Rozyk, Karina [1 ]
机构
[1] Mil Inst Med Warsaw, Dept Internal Med Pulmonol Allergy & Clin Immunol, Cent Clin Hosp, Minist Natl Def, Warsaw, Poland
[2] Natl Inst Geriatr Rheumatol & Rehabil, Dept Connect Tissue Dis, Warsaw, Poland
[3] Mil Inst Med Warsaw, Hematol & Flow Cytometry Lab, Dept Internal Med & Hematol, Cent Clin Hosp,Minist Natl Def, Warsaw, Poland
关键词
Biologics; CVID; DMARDS; Infections; Psoriatic arthritis; COMMON VARIABLE IMMUNODEFICIENCY; RHEUMATOID-ARTHRITIS; THERAPY; DISORDERS;
D O I
10.1007/s10067-017-3670-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 54-year-old man with confirmed psoriatic arthritis, treated with conventional and biologic disease-modifying anti-rheumatic drugs, suffered from severe, recurrent respiratory tract infections. He was found to have hypogammaglobulinemia. Further investigations confirmed the diagnosis of common variable immunodeficiency. Introduction of immunoglobulin G replacement therapy allowed for safe and effective treatment of psoriatic arthritis with etanercept and methotrexate. Patients with a history of recurrent infections on disease-modifying anti-rheumatic drugs and hypogammaglobulinemia should be assessed for primary antibody immunodeficiencies, even in adulthood.
引用
收藏
页码:1677 / 1681
页数:5
相关论文
共 50 条
  • [1] Recurrent infections in a patient with psoriatic arthritis and hypogammaglobulinemia, treated with conventional and biologic disease-modifying anti-rheumatic drugs—a primary or secondary entity?
    Ewa Więsik-Szewczyk
    Aleksandra Kucharczyk
    Katarzyna Świerkocka
    Elżbieta Rutkowska
    Karina Jahnz-Różyk
    [J]. Clinical Rheumatology, 2017, 36 : 1677 - 1681
  • [2] Recurrent infections in a rheumatoid arthritis patient with a primary immunodeficiency, treated with conventional and biologic disease-modifying anti-rheumatic drugs
    Diamantopoulos, Andreas P.
    Haugeberg, Glenn
    [J]. MODERN RHEUMATOLOGY, 2012, 22 (02) : 295 - 297
  • [3] IMPACT OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN LIPID PROFILE OF PSORIATIC ARTHRITIS PATIENTS
    Guajardo-Aldaco, Andrea L.
    Galarza-Delgado, Dionicio A.
    Azpiri-Lopez, Jose R.
    Colunga-Pedraza, Iris J.
    Cardenas-de la Garza, Jesus A.
    Arvizu-Rivera, Rosa I.
    Elizondo-Benitez, Maria F.
    Gonzalez-Gonzalez, Valeria
    [J]. ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [4] Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Choy, Ernest
    Aletaha, Daniel
    Behrens, Frank
    Finckh, Axel
    Gomez-Reino, Juan
    Gottenberg, Jacques-Eric
    Schuch, Florian
    Rubbert-Roth, Andrea
    [J]. RHEUMATOLOGY, 2017, 56 (05) : 689 - 697
  • [5] SECONDARY SARCOPENIA IN RHEUMATOID ARTHRITIS PATIENTS TREATED BY BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
    Hasegawa, Eriko
    Ito, Satoshi
    Kurosawa, Yoichi
    Kobayashi, Daisuke
    Abe, Asami
    Otani, Hiroshi
    Nakazono, Kiyoshi
    Murasawa, Akira
    Narita, Ichiei
    Ishikawa, Hajime
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1622 - 1622
  • [6] GUIDELINE ON CONVENTIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Galloway, James
    [J]. RHEUMATOLOGY, 2016, 55 : 14 - 14
  • [7] REAL-WORLD USAGE OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH PSORIATIC ARTHRITIS IN GERMANY
    Song, J.
    Anjohrin, S.
    Abe, C.
    Banefelt, J.
    Rieem, Dun A.
    Picker, N.
    Kromer, D.
    Fuchs, A.
    Hahn, P.
    Welby, S.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S305 - S305
  • [8] Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Number of Prior Biologic Disease-modifying Anti-rheumatic Drugs
    Mease, Philip
    Lertratanakul, Apinya
    Strober, Bruce
    Tsuji, Shigeyoshi
    Richette, Pascal
    Lovan, Charlie
    Feng, Dai
    Anderson, Jaclyn K.
    Van den Bosch, Filip
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [9] EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Mease, P. J.
    Lertratanakul, A.
    Strober, B.
    Tsuji, S.
    Richette, P.
    Lovan, C.
    Feng, D.
    Anderson, J.
    Van den Bosch, F.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 788 - 789
  • [10] Patterns in use and costs of conventional and biologic disease-modifying anti-rheumatic drugs in Australia
    Donges, E.
    Staatz, C. E.
    Benham, H.
    Kubler, P.
    Hollingworth, S. A.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2017, 35 (06) : 907 - 912